Harnessing competing endocytic pathways for overcoming the tumor-blood barrier: Magnetic resonance imaging and near-infrared imaging of bifunctional contrast media

Cancer Research

Volumn 69, Issue 13, 2009, Pages 5610-5617

  Migalovich, Helena Sheikhet ^a   Kalchenko, Vyacheslav ^a   Nevo, Nava ^a   Meir, Gila ^a   Kohen, Fortune ^a   Neeman, Michal ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE SERUM ALBUMIN; CONTRAST MEDIUM; CYTE777; DAIDZEIN; FLUORESCENT DYE; GADOLINIUM PENTETATE; NYSTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CAVEOLA; CELL LABELING; ENDOCYTOSIS; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO CULTURE; MOUSE; MYOFIBROBLAST; NEAR INFRARED REFLECTANCE SPECTROSCOPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PRIORITY JOURNAL; TUMOR BLOOD FLOW; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; ENDOCYTOSIS; FEMALE; HUMANS; ISOFLAVONES; MICE; MICE, NUDE; NYSTATIN; OVARIAN NEOPLASMS; PENTETIC ACID; SERUM ALBUMIN, BOVINE; TISSUE DISTRIBUTION;

EID: 67650422646     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4967     Document Type: Article

References (50)

1. Lazennec G. Estrogen receptor β, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer Lett 2006;231:151-7.
2. Schiffenbauer YS, Meir G, Maoz M, Even-Ram SC, Bar-Shavit R, Neeman M. Gonadotropin stimulation of MLS human epithelial ovarian carcinoma cells augments cell adhesion mediated by CD44 and by a (v)-integrin. Gynecol Oncol 2002;84:296-302.
3. Gilead A, Meir G, Neeman M. The role of angiogenesis, vascular maturation, regression and stroma infiltration in dormancy and growth of implanted MLS ovarian carcinoma spheroids. Int J Cancer 2004;108:524-31.
4. Neeman M, Dafni H, Bukhari O, Braun RD, Dewhirst MW. In vivo BOLD contrast MRI mapping of subcutaneous vascular function and maturation: validation by intravital microscopy. Magn Reson Med 2001;45:887-98.
5. Gilad AA, Israely T, Dafni H, Meir G, Cohen B, Neeman M. Functional and molecular mapping of uncoupling between vascular permeability and loss of vascular maturation in ovarian carcinoma xenografts: the role of stroma cells in tumor angiogenesis. Int J Cancer 2005;117:202-11.
6. Dafni H, Landsman L, Schechter B, Kohen F, Neeman M. MRI and fluorescence microscopy of the acute vascular response to VEGF165: vasodilation, hyperpermeability and lymphatic uptake, followed by rapid inactivation of the growth factor. NMR Biomed 2002;15:120-31.
7. Israely T, Nevo N, Harmelin A, Neeman M, Tsafriri A. Reducing ischaemic damage in rodent ovarian xenografts transplanted into granulation tissue. Hum Reprod 2006;21:1368-79.
8. Plaks V, Kalchenko V, Dekel N, Neeman M. MRI analysis of angiogenesis during mouse embryo implantation. Magn Reson Med 2006;55:1013-22.
9. Granot D, Kunz-Schughart LA, Neeman M. Labeling fibroblasts with biotin-BSA-GdDTPA-FAM for tracking of tumor-associated stroma by fluorescence and MR imaging. Magn Reson Med 2005;54:789-97.
10. Granot D, Addadi Y, Kalchenko V, Harmelin A, Kunz-Schughart LA, Neeman M. In vivo imaging of the systemic recruitment of fibroblasts to the angiogenic rim of ovarian carcinoma tumors. Cancer Res 2007;67:9180-9.
11. Stuart ES, Webley WC, Norkin LC. Lipid rafts, caveolae, caveolin-1, and entry by Chlamydiae into host cells. Exp Cell Res 2003;287:67-78.
12. Geninatti Crich S, Barge A, Battistini E, et al. Magnetic resonance imaging visualization of targeted cells by the internalization of supramolecular adducts formed between avidin and biotinylated Gd3+ chelates. J Biol Inorg Chem 2005;10:78-86.
13. Somjen D, Katzburg S, Nevo N, et al. A daidzeindaunomycin conjugate improves the therapeutic response in an animal model of ovarian carcinoma. J Steroid Biochem Mol Biol 2008;110:144-9.
14. Harris DM, Besselink E, Henning SM, Go VL, Heber D. Phytoestrogens induce differential estrogen receptor a- or h-mediated responses in transfected breast cancer cells. Exp Biol Med (Maywood) 2005;230:558-68.
15. Kohen F, Gayer B, Kulik T, et al. Synthesis and evaluation of the antiproliferative activities of derivatives of carboxyalkyl isoflavones linked to N-t-Bochexylenediamine. J Med Chem 2007;50:6405-10.
16. Geninatti Crich S, Cabella C, Barge A, et al. In vitro and in vivo magnetic resonance detection of tumor cells by targeting glutamine transporters with Gd-based probes. J Med Chem 2006;49:4926-36.
17. Sun C, Sze R, Zhang M. Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI. J Biomed Mater Res A 2006;78:550-7.
18. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res 2003;63:2723-7.
19. Dafni H, Gilead A, Nevo N, Eilam R, Harmelin A, Neeman M. Modulation of the pharmacokinetics of macromolecular contrast material by avidin chase: MRI, optical, and inductively coupled plasma mass spectrometry tracking of triply labeled albumin. Magn Reson Med 2003;50:904-14.
20. Hilderbrand SA, Kelly KA, Weissleder R, Tung CH. Monofunctional near-infrared fluorochromes for imaging applications. Bioconjug Chem 2005;16:1275-81.
21. Bhattacharya A, Seshadri M, Oven SD, Toth K, Vaughan MM, Rustum YM. Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs. Clin Cancer Res 2008;14:3926-32.
22. Bouzin C, Feron O. Targeting tumor stroma and exploiting mature tumor vasculature to improve anticancer drug delivery. Drug Resist Updat 2007;10:109-20.
23. Somjen D, Stern N, Knoll E, et al. Carboxy derivatives of isoflavones as affinity carriers for cytotoxic drug targeting in adrenocortical H295R carcinoma cells. J Endocrinol 2003;179:395-403.
24. Lehtonen JY, Adlercreutz H, Kinnunen PK. Binding of daidzein to liposomes. Biochim Biophys Acta 1996;1285:91-100.
25. Marquez DC, Chen HW, Curran EM, Welshons WV, Pietras RJ. Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Mol Cell Endocrinol 2006;246:91-100.
26. Gilad LA, Bresler T, Gnainsky J, Smirnoff P, Schwartz B. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells. J Endocrinol 2005;185:577-92.
27. Heberden C, Reine F, Grosse B, et al. Detection of a raft-located estrogen receptor-like protein distinct from ER a. Int J Biochem Cell Biol 2006;38:376-91.
28. Chojkier M. Inhibition of albumin synthesis in chronic diseases: molecular mechanisms. J Clin Gastroenterol 2005;39:5143-6.
29. Sharma R, Hook J, Kumar M, Gabra H. Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. Eur J Cancer 2008;44:251-6.
30. Atkins MB, Robertson MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997;3:409-17.
31. Frankel AE, Zuckero SL, Mankin AA, et al. Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous Tcell lymphoma. Curr Drug Targets 2009;10:104-9.
32. Hochhauser D, Meyer T, Spanswick VJ, et al. Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors. Clin Cancer Res 2009;15:2140-7.
33. Ohnuma T, Holland JF, Freeman A, Sinks LF. Biochemical and pharmacological studies with asparaginase in man. Cancer Res 1970;30:2297-305.
34. Bagley RG, Weber W, Rouleau C, Teicher BA. Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy. Cancer Res 2005;65:9741-50.
35. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335-48.
36. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002;8:2912-23.
37. McAlhany SJ, Ressler SJ, Larsen M, et al. Promotion of angiogenesis by ps20 in the differential reactive stroma prostate cancer xenograft model. Cancer Res 2003;63:5859-65.
38. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-401.
39. Sund M, Kalluri R. Tumor stroma derived biomarkers in cancer. Cancer Metastasis Rev 2009;28:177-83.
40. Bergamaschi A, Tagliabue E, Sorlie T, et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol 2008;214:357-67.
41. McIntosh DP, Tan XY, Oh P, Schnitzer JE. Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo : a pathway to overcome cell barriers to drug and gene delivery. Proc Natl Acad Sci U S A 2002;99:1996-2001.
42. Carver LA, Schnitzer JE. Caveolae: mining little caves for new cancer targets. Nat Rev Cancer 2003;3:571-81.
43. Teneriello MG, Tseng PC, Crozier M, et al. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol 2009;27:1426-31.
44. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317-24.
45. Perez EA. Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Res Treat 2009;114:195-201.
46. Karmali PP, Kotamraju VR, Kastantin M, et al. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine 2009;5:73-82.
47. Kurahashi N, Iwasaki M, Inoue M, Sasazuki S, Tsugane S. Plasma isoflavones and subsequent risk of prostate cancer in a nested case-control study: the Japan Public Health Center. J Clin Oncol 2008;26:5923-9.
48. Singh-Gupta VZH, Banerjee S, Kong D, Raffoul JJ, Sarkar FH, Hillman GG. Radiation-induced HIF-1a cell survival pathway is inhibited by soy isoflavones in prostate cancer cells. Int J Cancer 2009;124:1675-84.
49. Guha N, Kwan ML, Quesenberry CP, Jr., Weltzien EK, Castillo AL, Caan BJ. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. Breast Cancer Res Treat. In press 2009.
50. Eto I. "Nutritional and chemopreventive anti-cancer agents up-regulate expression of p27Kip1, a cyclin-dependent kinase inhibitor, in mouse JB6 epidermal and human MCF7, MDA-MB-321 and AU565 breast cancer cells." Cancer Cell Int 2006;6:20.